Clinical Trial Update: Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (Rosy Trial) evaluating Disitamab Vedotin ( RC48 ) in HR-positive, HER2-low metastatic breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: HR Positive/HER2 Low Expression Metastatic Breast Cancer | Phase 3 | Status: RECRUITING